Search

Displaying results 2491 - 2500 of 2960 in total
  1. Drug

    XP12B

    go.drugbank.com/drugs/DB04928
    Investigational

    It was granted Fast Track status for this indication by the FDA in November 2004.

  2. Drug

    ALMB-0166

    go.drugbank.com/drugs/DB17937
    Investigational

    It was granted FDA orphan designation in November 2018.[L47067]

  3. Drug

    Idarucizumab

    go.drugbank.com/drugs/DB09264
    Approved

    Approved under the tradename Praxbind (FDA), idarucizumab is indicated for the emergency treatment of dabigatran-associated bleeding in life-threatening or surgically induced situations.

  4. Drug

    Anthrax vaccine

    go.drugbank.com/drugs/DB11003
    ApprovedInvestigational

    [L47561] There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.

  5. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    [L49404] Lebrikizumab was also approved by the FDA on September 13, 2024.[L51379]

  6. Drug

    Galcanezumab

    go.drugbank.com/drugs/DB14042
    ApprovedInvestigational

    [A33112] Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache.

  7. Drug

    Toripalimab

    go.drugbank.com/drugs/DB15043
    ApprovedInvestigational

    [A262011,A262591] Toripalimab was granted FDA approval in October 2023 for the treatment of select patients with nasopharyngeal carcinomas.[L48696]

  8. Drug

    Serdexmethylphenidate

    go.drugbank.com/drugs/DB16629
    Approved

    [L32298, L32323] Serdexmethylphenidate was granted FDA approval on March 2, 2021, and is currently marketed as a combination capsule with [dexmethylphenidate] under the trademark AZSTARYS™ by KemPharm

  9. Drug

    Benzonatate

    go.drugbank.com/drugs/DB00868
    Approved

    Benzonatate was approved by the FDA in 1958 under the market name Tessalon Perles.

  10. Drug

    Dapagliflozin

    go.drugbank.com/drugs/DB06292
    ApprovedInvestigational

    [A261601] Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise.

    Products: Nra-dapagliflozin